Evaluation of ERRFI1 +808 T/G variant and its mRNA expression in coronary artery in-stent restenosis

One of the common treatments in cardiovascular disease as the first cause of death in the world is stent implantation. In-Stent Restenosis (ISR) is the major drawback of stent implantation. As there are several lines of evidence suggesting genetic factors involved in ISR, in this study we evaluated...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Gene reports 2021-09, Vol.24, p.101248, Article 101248
Hauptverfasser: Mehrpooya, Maryam, Asgarbeik, Saeedeh, Vahidi, Aida, Amoli, Mahsa Mohammad, Hosseini, Seyed Kianoosh
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:One of the common treatments in cardiovascular disease as the first cause of death in the world is stent implantation. In-Stent Restenosis (ISR) is the major drawback of stent implantation. As there are several lines of evidence suggesting genetic factors involved in ISR, in this study we evaluated the potential role of +808T/G polymorphism in ERRFI1 and its quantitative expression in the development of ISR. Individuals with ISR (n = 41) cases and Non-ISR (n = 51) controls, participated in this study. ERRFI1 gene expression in fresh un-stimulated PBMCs was determined in each group using quantitative real-time PCR. DNA extraction from the whole blood was performed using the phenol-chloroform method. The frequency of genotypes was determined by the PCR-RFLP technique. In spite of the higher amount of ERRFI1 expression in the control group (non-ISR), there were no statistically significant differences between ISR and non-ISR groups (p > 0.05). The expression of ERRFI1 was significantly different between ISR and Non-ISR groups only in patients with diabetes (p 
ISSN:2452-0144
2452-0144
DOI:10.1016/j.genrep.2021.101248